longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of death with atezo in adjuvant UC. There’s a strong rationale for circulating rather than tissue biomarkers here. Imvigor011 (randomised III) tests this prospectively

Last day at #EAU22, Outstanding plenary session and inspiring presentations on liquid biomarkers in #RCC
@AStenzl @grantissimus @TurajlicLab @ZeynepZengin @srossi725
@EAUYAU_RenalCa @Uroweb @AmerUrological @KidneyCancer

What a force @ZeynepZengin is! So proud of her for delivering such a fantastic talk about the role of liquid biopsies in guiding treatment selection in RCC. Learning from the best, of course! @montypal #EAU22 #RCC

#EAU22 lot of discussion going on in abstract session on #prostatecancer biomarkers + #MRI in the new format @uroweb